

Tocilizumab for the management of immune mediated blockade

Journal of Oncology Pharmacy Practice

25, 551-557

DOI: 10.1177/1078155217745144

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Two-Faced Cytokine IL-6 in Host Defense and Diseases. International Journal of Molecular Sciences, 2018, 19, 3528.	4.1	143
2	A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. , 2018, 6, 156.		58
3	Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation. , 2018, 6, 153.		29
4	Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer. Chest, 2018, 154, 1416-1423.	0.8	230
5	Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis. Clinical and Translational Gastroenterology, 2018, 9, e180.	2.5	74
7	A Review of Immune-Mediated Adverse Events in Melanoma. Oncology and Therapy, 2019, 7, 101-120.	2.6	23
8	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. Arthritis and Rheumatology, 2019, 71, 2100-2111.	5.6	202
9	Emerging trends in immunotherapy for pediatric sarcomas. Journal of Hematology and Oncology, 2019, 12, 78.	17.0	59
10	Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. , 2019, 7, 169.		28
11	Immune regulation and cytotoxic T cell activation of IL-10 agonists “ Preclinical and clinical experience. Seminars in Immunology, 2019, 44, 101325.	5.6	30
12	Testing Immune-Related Adverse Events in Cancer Immunotherapy. Clinics in Laboratory Medicine, 2019, 39, 669-683.	1.4	3
13	Immune checkpoint inhibitor“related luminal GI adverse“events. Gastrointestinal Endoscopy, 2019, 90, 881-892.	1.0	24
14	Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Review of Clinical Immunology, 2019, 15, 813-822.	3.0	221
15	Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer, 2019, 19, 558.	2.6	106
16	Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature. RMD Open, 2019, 5, e000906.	3.8	59
17	Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab. Immunotherapy, 2019, 11, 1527-1531.	2.0	12
18	Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481988419.	3.2	62
19	Checkpoint Inhibitor“Associated Autoimmunity. Journal of Clinical Rheumatology, 2019, Publish Ahead of Print, .	0.9	0

#	ARTICLE	IF	CITATIONS
21	Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2020, 25, 197-202.	3.7	12
22	Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus. <i>Internal Medicine</i> , 2020, 59, 569-572.	0.7	8
23	An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors. <i>Digestion</i> , 2020, 101, 60-65.	2.3	12
24	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. <i>Thoracic Cancer</i> , 2020, 11, 191-197.	1.9	52
25	Management of the Adverse Effects of Immune Checkpoint Inhibitors. <i>Vaccines</i> , 2020, 8, 575.	4.4	29
26	Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice. <i>Current Opinion in Oncology</i> , 2020, 32, 603-612.	2.4	5
27	Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation. <i>Frontiers in Oncology</i> , 2020, 10, 1785.	2.8	35
28	Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6. <i>Communications Biology</i> , 2020, 3, 571.	4.4	31
29	Management of Immune Checkpoint Inhibitor-Related Rheumatological Toxicities. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020, 20, 25-34.	0.4	0
30	Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting. <i>JACC: CardioOncology</i> , 2020, 2, 491-502.	4.0	20
31	Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction. <i>Leukemia Research Reports</i> , 2020, 14, 100228.	0.4	2
32	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <i>Journal of Autoimmunity</i> , 2020, 114, 102514.	6.5	37
33	Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?. <i>Pharmaceuticals</i> , 2020, 13, 166.	3.8	16
34	Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS. <i>Medicina (Lithuania)</i> , 2020, 56, 377.	2.0	15
35	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <i>Lancet Oncology</i> , The, 2020, 21, e398-e404.	10.7	74
36	Programmed cell death 1 (PD-1)/PD-ligand 1 (PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 299-304.	1.1	10
37	Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor-associated adverse events. <i>Thoracic Cancer</i> , 2020, 11, 2077-2086.	1.9	1
38	Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2. <i>Frontiers in Oncology</i> , 2020, 10, 1555.	2.8	5

#	ARTICLE	IF	CITATIONS
39	Strategies for improving the management of immune-related adverse events. , 2020, 8, e001754.		60
40	Full Issue PDF. JACC: CardioOncology, 2020, 2, I-CLXXX.	4.0	0
41	Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. Expert Review of Clinical Immunology, 2020, 16, 1185-1204.	3.0	23
42	When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. , 2020, 8, e001322.		26
43	Angiotensinâ€converting enzyme 2 (<scp>ACE2</scp>), <scp>SARSâ€CoV</scp>â€2 and the pathophysiology of coronavirus disease 2019 (<scp>COVID</scp>â€19). Journal of Pathology, 2020, 251, 228-248.	4.5	791
44	Immune-related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers, 2020, 6, 38.	30.5	684
45	Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. Current Oncology Reports, 2020, 22, 56.	4.0	23
46	Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy. , 2020, 8, e000898.		3
47	COVID-19 and immune checkpoint inhibitors: initial considerations. , 2020, 8, e000933.		45
48	The COVID-19 Pandemic and its Impact on the Cardio-Oncology Population. Current Oncology Reports, 2020, 22, 60.	4.0	31
49	Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort. Autoimmunity Reviews, 2020, 19, 102595.	5.8	44
50	Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer. Current Opinion in Pulmonary Medicine, 2020, 26, 326-340.	2.6	10
51	Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. , 2020, 8, e000984.		15
52	COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination. Brain Sciences, 2020, 10, 345.	2.3	38
53	Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab. Clinical Lung Cancer, 2020, 21, e547-e550.	2.6	13
54	Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanomaâ€”An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer. International Journal of Molecular Sciences, 2020, 21, 2020.	4.1	18
55	Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy, 2020, 12, 269-273.	2.0	188
56	Moving towards personalized treatments of immune-related adverse events. Nature Reviews Clinical Oncology, 2020, 17, 504-515.	27.6	189

#	ARTICLE	IF	CITATIONS
57	Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. Hepatology, 2020, 72, 315-329.	7.3	131
58	Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. , 2020, 8, e000842.		126
59	SARS, MERS and COVID-19: clinical manifestations and organ-system complications: a mini review. Pathogens and Disease, 2020, 78, .	2.0	55
60	The Impact of COVID-19 on Cancer Risk and Treatment. Cellular and Molecular Bioengineering, 2020, 13, 285-291.	2.1	33
61	Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy. Cancer Immunology, Immunotherapy, 2020, 69, 1101-1112.	4.2	13
62	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 307-319.	3.7	310
63	A review of cancer immunotherapy toxicity. Ca-A Cancer Journal for Clinicians, 2020, 70, 86-104.	329.8	753
64	The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy. Current Opinion in Rheumatology, 2020, 32, 175-183.	4.3	1
65	Commentary: Obesity: The “Achilles heel” for COVID-19?. Metabolism: Clinical and Experimental, 2020, 108, 154251.	3.4	182
66	Autoimmune complications of immunotherapy: pathophysiology and management. BMJ, The, 2020, 369, m736.	6.0	79
68	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
69	Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19. Cancer Discovery, 2020, 10, 775-778.	9.4	28
70	COVID-19 and the Heart. Circulation Research, 2020, 126, 1443-1455.	4.5	574
71	Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Annals of Oncology, 2020, 31, 724-744.	1.2	129
72	Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases. Journal of Oncology Pharmacy Practice, 2021, 27, 739-746.	0.9	18
73	Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors “is it time for a paradigm shift?. Clinical Rheumatology, 2021, 40, 1687-1695.	2.2	15
74	Implications of metabolism-driven myeloid dysfunctions in cancer therapy. Cellular and Molecular Immunology, 2021, 18, 829-841.	10.5	21
75	Future perspective: biologic agents in patients with severe COVID-19. Immunopharmacology and Immunotoxicology, 2021, 43, 1-7.	2.4	26

#	ARTICLE	IF	CITATIONS
76	Tocilizumab for COVID-19 Pneumonia in a Patient With Nonâ€“Small-cell Lung Cancer Treated With Chemoimmunotherapy. <i>Clinical Lung Cancer</i> , 2021, 22, e67-e69.	2.6	11
77	Management of Rheumatic Immune-Related Adverse Events (irAEs): General Principles. , 2021, , 309-321.		0
78	Review of immune checkpoint inhibitors in immuno-oncology. <i>Advances in Pharmacology</i> , 2021, 91, 111-139.	2.0	43
79	Critical Analysis of Immune Checkpoint Inhibitor Immunotoxicity Management. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 84-94.	0.6	0
80	Cancer Immunotherapy in Patients with Preexisting Inflammatory Arthritis. , 2021, , 273-291.		0
81	Revisiting immunogenic cell death to improve treatment response in cancer. , 2021, , 65-90.		4
82	SARS-COV-2 infection and lung tumor microenvironment. <i>Molecular Biology Reports</i> , 2021, 48, 1925-1934.	2.3	22
83	The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease. <i>Frontiers in Oncology</i> , 2021, 11, 625872.	2.8	25
84	Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis. <i>Cancers</i> , 2021, 13, 652.	3.7	19
85	Shifting From a â€œOne Size Fits Allâ€“to a Tailored Approach for Immune-Related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 183-186.	1.1	4
86	Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Eventsâ€“A Comprehensive Review. <i>Frontiers in Oncology</i> , 2020, 10, 585311.	2.8	69
87	Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 537-547.	2.4	9
88	Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID-19 therapy. <i>Genomics</i> , 2021, 113, 564-575.	2.9	12
89	Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Clinical Science</i> , 2021, 135, 703-724.	4.3	18
90	Beyond immune checkpoint blockade: emerging immunological strategies. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 899-919.	46.4	208
91	Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. <i>Trends in Immunology</i> , 2021, 42, 293-311.	6.8	62
92	IL-6 modulation for COVID-19: the right patients at the right time?. , 2021, 9, e002285.		32
93	Adverse events induced by immune checkpoint inhibitors. <i>Current Opinion in Immunology</i> , 2021, 69, 29-38.	5.5	25

#	ARTICLE	IF	CITATIONS
94	Inflammatory markers in autoimmunity induced by checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1623-1630.	2.5	24
95	Peripheral blood interleukin 6, interleukin 10, and T lymphocyte levels are associated with checkpoint inhibitor induced pneumonitis: a case report. <i>Acta Oncologica</i> , 2021, 60, 813-817.	1.8	6
96	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. <i>Circulation Research</i> , 2021, 128, 1780-1801.	4.5	48
97	Cytokine storm induced by a PD1 inhibitor in a renal transplant patient. <i>American Journal of Transplantation</i> , 2021, 21, 2616-2618.	4.7	8
98	Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer. <i>Journal of Investigative Medicine</i> , 2021, 69, 1281-1286.	1.6	0
99	Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. <i>Cancers</i> , 2021, 13, 2931.	3.7	19
100	Treatment of steroid-resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report. <i>Thoracic Cancer</i> , 2021, 12, 2214-2216.	1.9	5
101	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
102	Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. <i>Nature Medicine</i> , 2021, 27, 1646-1654.	30.7	65
103	Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 698832.	2.8	27
105	Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients. <i>Immuno</i> , 2021, 1, 253-263.	1.5	11
106	Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1711-1720.	2.5	22
107	Immune checkpoint inhibitor-related hepatotoxicity: A review. <i>World Journal of Gastroenterology</i> , 2021, 27, 5376-5391.	3.3	52
108	Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. <i>European Journal of Internal Medicine</i> , 2021, 93, 87-94.	2.2	41
109	Anti-Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	18
110	Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 720759.	2.8	3
111	Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma. <i>Internal Medicine</i> , 2021, 60, 3025-3029.	0.7	10
112	Cutaneous adverse events caused by immune checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 956-966.	1.2	59

#	ARTICLE	IF	CITATIONS
113	Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. European Journal of Cancer, 2021, 157, 214-224.	2.8	62
114	Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity. SSRN Electronic Journal, 0, , .	0.4	0
115	Checkpoint Inhibitors and Hepatotoxicity. Biomedicines, 2021, 9, 101.	3.2	17
116	Immune-Related Adverse Events: Pneumonitis. Advances in Experimental Medicine and Biology, 2020, 1244, 255-269.	1.6	38
117	The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs). Thoracic Cancer, 2020, 11, 835-839.	1.9	43
118	COVID-19 and lung cancer: risks, mechanisms and treatment interactions. , 2020, 8, e000892.		43
119	Rheumatic and Musculoskeletal Adverse Events with Immune Checkpoint Inhibitors: Data from the United States Food and Drug Administration Adverse Event Reporting System. Journal of Immunotherapy and Precision Oncology, 2019, 2, 65-73.	1.4	8
120	Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1287-1290.	4.9	5
121	Immuno-oncologic care during COVID-19: Challenges and opportunities for improving clinical care and investigation. , 2021, 2, 75-82.		1
122	Checkpoint inhibitor pneumonitis: Short review of literature and case report. Memo - Magazine of European Medical Oncology, 0, , 1.	0.5	3
123	Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. Frontiers in Pharmacology, 2021, 12, 743582.	3.5	14
124	Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis. Biomedicines, 2021, 9, 1484.	3.2	10
125	The Use of Checkpoint Inhibitors in Classical Hodgkin's Lymphoma during the COVID-19 Pandemic (Pirogov Medical Center's Experience). Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 307-315.	0.4	1
126	Differential diagnosis of pneumonia in pediatric patients with oncohematological disease in condition of new coronavirus infection COVID-19. Russian Journal of Pediatric Hematology and Oncology, 2020, 7, 104-111.	0.3	1
127	Immune-related Pulmonary Toxicity From Cancer Immunotherapy: A Systematic Approach. Clinical Pulmonary Medicine, 2020, 27, 183-192.	0.3	0
130	Hepatobiliary and Pancreatic Adverse Events. Advances in Experimental Medicine and Biology, 2021, 1342, 339-355.	1.6	6
131	Pulmonary Toxicities of Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1342, 357-375.	1.6	4
132	Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition. , 2022, 10, e003551.		19

#	ARTICLE	IF	CITATIONS
133	Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors. <i>Neurotherapeutics</i> , 2022, 19, 848-863.	4.4	10
134	Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature. <i>Frontiers in Immunology</i> , 2022, 13, 807050.	4.8	30
135	Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury. <i>Frontiers in Pharmacology</i> , 2021, 12, 786174.	3.5	8
136	Immune-related adverse events in various organs caused by immune checkpoint inhibitors. <i>Allergology International</i> , 2022, 71, 169-178.	3.3	34
137	Immune-checkpoint inhibitors: long-term implications of toxicity. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 254-267.	27.6	360
138	Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, 43.	3.5	4
139	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. <i>Frontiers in Immunology</i> , 2022, 13, 804597.	4.8	27
140	Checkpoint inhibitor/interleukin-6 based combination therapy of cancer. <i>Cancer Medicine</i> , 2022, 11, 2934-2943.	2.8	25
141	COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery. <i>Biomedicines</i> , 2022, 10, 776.	3.2	8
142	Novel Immunotherapies for Osteosarcoma. <i>Frontiers in Oncology</i> , 2022, 12, 830546.	2.8	25
143	Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism. <i>Frontiers in Immunology</i> , 2022, 13, 830631.	4.8	28
144	Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events. <i>Clinical Cancer Research</i> , 2022, 28, 1250-1257.	7.0	11
147	Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors. <i>Materials and Design</i> , 2022, 219, 110738.	7.0	0
148	Analysis of the mechanisms of development of neurorheumatological consequences of COVID-19 and the possibility of their pharmacological correction. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 92-98.	0.5	1
149	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6.	16.8	115
150	IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy. <i>Cancer Cell</i> , 2022, 40, 450-451.	16.8	8
151	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. <i>ESMO Open</i> , 2022, 7, 100474.	4.5	3
152	Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. <i>Cancers</i> , 2022, 14, 2460.	3.7	2

#	ARTICLE	IF	CITATIONS
153	Monitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives. Journal of Inflammation Research, 0, Volume 15, 3105-3118.	3.5	6
154	Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Instituteâ€”Cancer Therapy Evaluation Program. Journal of Clinical Oncology, 2022, 40, 3439-3452.	1.6	24
155	Immune checkpoint inhibitorâ€”related cholangiopathy: Novel clinicopathological description of a multiâ€”centre cohort. Liver International, 2023, 43, 147-154.	3.9	16
156	Clinical Patterns and Follow-Up of Inflammatory Arthritis and Other Immune-Related Adverse Events Induced by Checkpoint Inhibitors. A Multicenter Study. Frontiers in Medicine, 0, 9, .	2.6	9
157	Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis. Biomedicines, 2022, 10, 1334.	3.2	5
158	Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management. Frontiers in Medicine, 0, 9, .	2.6	4
159	Current status and prospects of IL-6â€”targeting therapy. Expert Review of Clinical Pharmacology, 2022, 15, 575-592.	3.1	10
160	Mechanisms of dermatological toxicities to immune checkpoint inhibitor cancer therapies. Clinical and Experimental Dermatology, 2022, 47, 1928-1942.	1.3	6
161	Clinical Outcomes after Immunotherapies in Cancer Setting during COVID-19 Era: A Systematic Review and Meta-Regression. Reports, 2022, 5, 31.	0.5	0
162	Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. Frontiers in Oncology, 0, 12, .	2.8	4
163	The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. Frontiers in Oncology, 0, 12, .	2.8	16
164	Immune checkpoint Inhibitorâ€”Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. Cancer Treatment Reviews, 2022, 109, 102440.	7.7	28
165	Hepatology (Liver and Bile Duct). , 2022, , 119-165.		0
166	Gastroenterology (GI). , 2022, , 81-96.		0
167	Phase 2 Study of Ipilimumab, Nivolumab, and Tocilizumab Combined with Stereotactic Body Radiotherapy in Patients with Refractory Pancreatic Cancer (TRIPLE-R). SSRN Electronic Journal, 0, , .	0.4	0
168	Phase 2 Study of Ipilimumab, Nivolumab, and Tocilizumab Combined with Stereotactic Body Radiotherapy in Patients with Refractory Pancreatic Cancer (TRIPLE-R). SSRN Electronic Journal, 0, , .	0.4	0
169	Immune Checkpoint Inhibitor-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Squamous Cell Carcinoma. Journal of Hematology (Brossard, Quebec), 2022, 11, 142-147.	1.0	6
170	External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition. Frontiers in Immunology, 0, 13, .	4.8	6

#	ARTICLE	IF	CITATIONS
171	Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
172	Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	2.0	4
173	COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. , 2022, 10, e005111.		17
174	PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
175	Autoimmune and autoinflammatory manifestations in inborn errors of immunity. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2022, 22, 343-351.	2.3	3
176	Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies. <i>Translational Lung Cancer Research</i> , 2022, 11, 1835-1846.	2.8	2
178	Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management. <i>Journal of Clinical Medicine</i> , 2022, 11, 5977.	2.4	2
179	Evaluation of the Tocilizumab therapy in human cancers: Latest evidence and clinical potential. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 2360-2368.	1.5	1
180	Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study. <i>RMD Open</i> , 2022, 8, e002612.	3.8	6
181	Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor. <i>Thoracic Cancer</i> , 2022, 13, 3420-3430.	1.9	5
182	Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events. , 2022, 10, e005635.		11
183	Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2022, 33, 1217-1238.	1.2	204
184	Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 2289-2305.	2.8	6
185	Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review. , 2023, 1, 46-55.		1
186	Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). <i>European Journal of Cancer</i> , 2023, 180, 125-133.	2.8	7
187	Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
188	Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	13
190	Cardiovascular, Renal and Pulmonary Toxicity of Immune Checkpoint Inhibitors in Cancer: What the GP Should Know. <i>Praxis</i> , 2023, 112, 160-171.	0.4	1

#	ARTICLE	IF	CITATIONS
191	Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines. <i>Cancers</i> , 2023, 15, 1170.	3.7	0
192	How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles. <i>Cancers</i> , 2023, 15, 1324.	3.7	1
193	Management of the adverse effects of cancer immunotherapy with a focus on the respiratory and nervous systems. <i>Journal of the Korean Medical Association</i> , 2023, 66, 116-122.	0.3	0
194	Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
195	Current landscape and tailored management of immune-related adverse events. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	1
196	Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitorsâ€™A 2023 Update. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5643.	4.1	7
197	Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
198	Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus. <i>European Journal of Cancer</i> , 2023, 187, 36-57.	2.8	1
199	Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer. <i>Current Oncology</i> , 2023, 30, 3672-3683.	2.2	1
200	Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. , 2023, 11, e006398.		22
201	Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
202	Tacrolimus for the Management of Delayed Onset and Treatment-Refractory Immune-Related Hepatitis. <i>ACG Case Reports Journal</i> , 2023, 10, e01007.	0.4	2
203	Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy. <i>Pathology Research and Practice</i> , 2023, 247, 154473.	2.3	1
204	Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review. <i>Kurume Medical Journal</i> , 2021, 68, 43-52.	0.1	1
205	Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. <i>Npj Precision Oncology</i> , 2023, 7, .	5.4	12
206	Cytokine release syndrome and cancer immunotherapies â€™ historical challenges and promising futures. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
207	Immune-related adverse events of immune checkpoint inhibitors: a review. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	18
208	Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitorâ€™induced colitis. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	12

#	ARTICLE	IF	CITATIONS
209	Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. , 2023, 11, e006814.		8
210	An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management. Frontiers in Immunology, 0, 14, .	4.8	1
211	Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors. Frontiers in Neuroscience, 0, 17, .	2.8	1
212	Treatment of Refractory Checkpoint-Inhibitor-Induced Hepatitis with Tacrolimus: A Case and Review of the Literature. International Journal of Translational Medicine, 2023, 3, 274-285.	0.4	0
213	Tocilizumab in grade 4 hepatitis secondary to immune checkpoint inhibitor: a case report and review of the literature. Immunotherapy, 2023, 15, 1125-1132.	2.0	3
214	Checkpoint Inhibitor-Induced Pneumonitis: Incidence and Management. Current Pulmonology Reports, 0, , .	1.3	0
215	Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies. JAMA Network Open, 2023, 6, e2323098.	5.9	5
216	Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil. Clinical Journal of Gastroenterology, 2023, 16, 720-725.	0.8	2
217	Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1stâ€“3rd, 2022â€“Naples,) Tj ETQo0 0 0 rgBT /Overl	4.4	2
218	Antiâ€“PDâ€“1/PDâ€“L1 and antiâ€“CTLAâ€“4 associated checkpoint inhibitor pneumonitis in nonâ€“small cell lung cancer: Occurrence, pathogenesis and risk factors (Review). International Journal of Oncology, 2023, 63, .	3.3	0
219	Pathogenesis, pathological characteristics and individualized therapy for immune-related adverse effects. , 2023, , .		0
220	A Potential New Use for Tocilizumab: Refractory Checkpoint Inhibitor Hepatitis. ACG Case Reports Journal, 2023, 10, e01162.	0.4	1
221	Considerations and Approaches for Cancer Immunotherapy in the Aging Host. Cancer Immunology Research, 0, , OF1-OF13.	3.4	0
222	Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach. Inflammatory Bowel Diseases, 0, , .	1.9	1
223	Cytokine Response to Nanoparticles Bearing Nucleic Acid Cargo. Studies in Mechanobiology, Tissue Engineering and Biomaterials, 2023, , 229-266.	1.0	0
224	Treatment of Myositis Associated With Immune Checkpoint Inhibitors. Current Treatment Options in Rheumatology, 0, , .	1.4	0
225	Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases. Oncoimmunology, 2023, 12, .	4.6	1
226	Immune Checkpoint Inhibition. , 2024, , 1-91.		0

#	ARTICLE	IF	CITATIONS
227	Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor–induced CNS inflammation. EBioMedicine, 2024, 100, 104955.	6.1	1
228	Pulmonary toxicity of immune checkpoint immunotherapy. Journal of Clinical Investigation, 2024, 134, .	8.2	2
229	Corticosteroid-resistant immune-related adverse events: a systematic review. , 2024, 12, e007409.		0
230	The ABC of Immune-Mediated Hepatitis during Immunotherapy in Patients with Cancer: From Pathogenesis to Multidisciplinary Management. Cancers, 2024, 16, 795.	3.7	0
231	Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management. Frontiers in Immunology, 0, 15, .	4.8	0
232	Immune–related adverse events in non–small cell lung cancer: Occurrence, mechanisms and therapeutic strategies. Clinical and Translational Medicine, 2024, 14, .	4.0	0
233	Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease-Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy. Rheumatic Disease Clinics of North America, 2024, 50, 337-357.	1.9	0
234	Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity. , 2024, 12, e008482.		0
235	Neurologic manifestations of autoimmunity with immune checkpoint inhibitors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 449-465.	1.8	0